Publication date: Sep 09, 2019
The national opioid epidemic requires development of real-world evidence based treatments for opioid use disorder, including adjuncts to Medication Assisted Treatment (MAT) with buprenorphine. Interventions are needed that address the complex needs of patients with opioid use disorder, which include substantial mental health co-morbidity and high rates of chronic pain related to the complex interaction of opioid prescribing for pain and opioid use disorder. This study leverages recent federal and state opioid use disorder treatment initiatives as a platform for testing a promising mind-body intervention, Mindful Awareness in Body-oriented Therapy (MABT) as an adjunct to MAT in two clinical settings. MABT, a novel mindfulness-based intervention, uniquely addresses aspects of awareness, interoception, and regulation that may be associated with pain, mental health distress, and behavioral control that increase risk of relapse and poor treatment outcomes. Using a randomized, two-group, repeated measures design, we will compare those who receive MABT+ MAT to MAT only. The primary aim is to evaluate the effectiveness of MABT + MAT compared to MAT only in reducing opioid use and other substances. Assessments will be administered at baseline, post-intervention, and at 24 weeks follow-up.
|drug||DRUGBANK||Ilex paraguariensis leaf|
- Experts: Find alternatives before opioids for pain relief
- Testing a support programme for opioid reduction for people with chronic non-malignant pain: the I-WOTCH randomised controlled trial protocol.
- Opioid Addiction, Genetic Susceptibility, and Medical Treatments: A Review.
- SMART Trial for Medication Assisted Treatment Adherence